(0.21%) 5 142.50 points
(0.21%) 38 521 points
(0.32%) 17 902 points
(-0.99%) $83.02
(1.72%) $1.956
(-0.26%) $2 341.00
(-0.16%) $27.49
(0.39%) $925.70
(-0.16%) $0.933
(-0.09%) $11.02
(-0.24%) $0.798
(0.73%) $92.54
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.61%
@ $80.96
Išleistas: 25 bal. 2024 @ 22:38
Grąža: 0.01%
Ankstesnis signalas: bal. 25 - 19:49
Ankstesnis signalas:
Grąža: 0.63 %
Live Chart Being Loaded With Signals
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 435 170 |
Vidutinė apimtis | 831 755 |
Rinkos kapitalizacija | 11.15B |
EPS | $0 ( 2024-02-13 ) |
Kita pelno data | ( $0.460 ) 2024-05-02 |
Last Dividend | $0.0500 ( 2024-02-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.92 |
ATR14 | $1.870 (2.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-16 | Laukien Frank H | Sell | 1 404 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Buy | 10 000 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Buy | 5 000 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Sell | 13 772 | Common Stock |
2024-03-04 | Requardt Hermann Fritz | Sell | 1 228 | Common Stock |
INSIDER POWER |
---|
-31.65 |
Last 100 transactions |
Buy: 483 678 | Sell: 1 126 200 |
Tūris Koreliacija
Bruker Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
SVFA | 0.921 |
SKYA | 0.916 |
AEAC | 0.915 |
PPTA | 0.914 |
ARRW | 0.913 |
AMTBB | 0.912 |
LFAC | 0.911 |
INTE | 0.911 |
ESCA | 0.91 |
HORI | 0.91 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
BMRA | -0.919 |
BWB | -0.911 |
HRMY | -0.91 |
SLN | -0.906 |
INCR | -0.903 |
SFST | -0.903 |
EQBK | -0.902 |
PEAR | -0.902 |
PMVP | -0.902 |
CSSEP | -0.901 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bruker Corp Koreliacija - Valiuta/Žaliavos
Bruker Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $2.96B |
Bruto pelnas: | $1.52B (51.17 %) |
EPS: | $2.92 |
FY | 2023 |
Pajamos: | $2.96B |
Bruto pelnas: | $1.52B (51.17 %) |
EPS: | $2.92 |
FY | 2022 |
Pajamos: | $2.53B |
Bruto pelnas: | $1.31B (51.59 %) |
EPS: | $2.00 |
FY | 2022 |
Pajamos: | $2.53B |
Bruto pelnas: | $1.31B (51.59 %) |
EPS: | $2.00 |
Financial Reports:
No articles found.
Bruker Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0.0500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0400 | 2016-03-02 |
Last Dividend | $0.0500 | 2024-02-29 |
Next Dividend | $0 | N/A |
Payout Date | 2024-03-15 | |
Next Payout Date | N/A | |
# dividends | 33 | -- |
Total Paid Out | $1.410 | -- |
Avg. Dividend % Per Year | 0.21% | -- |
Score | 4.59 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.12 | |
Div. Directional Score | 8.92 | -- |
Year | Amount | Yield |
---|---|---|
2016 | $0.160 | 0.68% |
2017 | $0.160 | 0.74% |
2018 | $0.160 | 0.46% |
2019 | $0.160 | 0.55% |
2020 | $0.160 | 0.31% |
2021 | $0.160 | 0.30% |
2022 | $0.200 | 0.25% |
2023 | $0.200 | 0.29% |
2024 | $0.0500 | 0.07% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.144 | 1.500 | 7.12 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.101 | 1.200 | 6.65 | 7.98 | [0 - 0.3] |
returnOnEquityTTM | 0.338 | 1.500 | 7.35 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0688 | -1.000 | 9.31 | -9.31 | [0 - 1] |
currentRatioTTM | 1.800 | 0.800 | 6.00 | 4.80 | [1 - 3] |
quickRatioTTM | 0.933 | 0.800 | 9.22 | 7.37 | [0.8 - 2.5] |
cashRatioTTM | 0.406 | 1.500 | 8.85 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.303 | -1.500 | 4.94 | -7.42 | [0 - 0.6] |
interestCoverageTTM | -11.98 | 1.000 | -5.55 | -5.55 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.41 | 2.00 | 9.20 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.671 | 2.00 | 9.16 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.936 | -1.500 | 6.26 | -9.38 | [0 - 2.5] |
grossProfitMarginTTM | 0.510 | 1.000 | 4.84 | 4.84 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.149 | 1.000 | 9.02 | 9.02 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.272 | 1.000 | 9.60 | 9.60 | [0.2 - 2] |
assetTurnoverTTM | 0.698 | 0.800 | 8.68 | 6.95 | [0.5 - 2] |
Total Score | 11.71 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.58 | 1.000 | 7.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.338 | 2.50 | 8.30 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.671 | 2.00 | 9.44 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.247 | 1.500 | 3.82 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.41 | 2.00 | 9.20 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0688 | 1.500 | 9.31 | -9.31 | [0 - 1] |
pegRatioTTM | 0.361 | 1.500 | -0.929 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.118 | 1.000 | 9.55 | 0 | [0.1 - 0.5] |
Total Score | 6.12 |
Bruker Corp
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.